• Program
• Schedule

• Abstract Book

※If you have registered for participation, please enter the password provided by the secretariat.

• Presidential Lecture
• Special Lecture
• Symposium
• Plenary Session
• Educational Lecture
• Oral Session
• Encore（Oral Session）
• Poster Session
• Encore（Poster Session）
• Sponsored Seminar
• Morning Seminar
• Luncheon Seminar

Presidential LectureDrug discovery for myeloma from new perspectives of pathophysiology

May 27 (Sat.) 13:30～14:00 Room 1 (5F Main Hall)

Chairperson:

• Masahiro Abe(Kawashima Hospital)

Speaker:

• Yutaka Hattori(Division of Clinical Physiology and Therapeutics, Keio University Faculty of Pharmacy / Department of Hematology, Tokyo Saiseikai Central Hospital)

Special Lecture 1Cutting edge of biology in post-genome era

May 27 (Sat.) 15:10～16:20 Room 1 (5F Main Hall)

Chairpersons:

• Yutaka Hattori(Keio University / Tokyo Saiseikai Central Hospital)
• Mineo Kurokawa(The University of Tokyo)

Function of extracellular vesicles in lymphoproliferative disease

Speaker:

• Ai Kotani(Tokai University School of Medicine Advanced Medical Science)

Intracellular quality control by autophagy

Speaker:

• Noboru Mizushima(Department of Biochemistry and Molecular Biology, Graduate School of Medicine, The University of Tokyo)

Special Lecture 2Up-to-date of COVID-19 clinics

May 28 (Sun.) 13:50～15:00 Room 1 (5F Main Hall)

Chairpersons:

• Hiroshi Handa(Gunma University)
• Takahide Kikuchi(Tokyo Saiseikai Central Hospital)

Current status and future prospects of COVID-19 treatment

Speaker:

• Norio Ohmagari(Disease Control and Prevention Center, National Center for Global Health and Medicine)

Management of patients with hematological disorders in the prolonged COVID-19 pandemic

Speaker:

• Masao Hagihara(Department of Hematology, Eiju General Hospitlal, Japan)

Symposium 1New developments of immunotherapy

May 27 (Sat.) 9:00～10:15 Room 1 (5F Main Hall)

Chairpersons:

• Yoichi Imai(Dokkyo Medical University)
• Maiko Matsushita(Keio University)

From basic and clinical studies of monoclonal antibodies for MM to the current and future status of therapy of CAR-T cell and bispecific antibodies

Speaker:

• Yoichi Imai(Department of Hematology and Oncology, Dokkyo Medical University)

Recent Advances of Bispecific Antibody Therapy for Myeloma

Speaker:

• Toshiki Ochi(Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine / Division of Immune Regulation, Proteo - Science Center, Ehime University)

Cancer immunotherapy to cure patients with multiple myeloma

Speaker:

• Yuki Kagoya(Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine)

Symposium 2“Molecular pathogenesis and treatment of high-risk myeloma”

May 27 (Sat.) 14:10～15:00 Room 1 (5F Main Hall)

Chairpersons:

• Akira Sakai(Fukushima Medical University)
• Yasushi Takamatsu(Fukuoka University)

Genomic risk in multiple myeloma

Speaker:

• Hervé Avet-Loiseau(IUC-ONCOPOLE, France)

Molecular pathogenesis and treatment approach of myeloma with high-risk cytogenetics

Speaker:

• Ichiro Hanamura(Division of Hematology, Department of Internal Medicine, Aichi Medical University, Japan)

Symposium 3“International symposium: Progress in myeloma therapy: current status and future perspective”

May 28 (Sun.) 9:00～10:05 Room 1 (5F Main Hall)

Chairpersons:

• Hiroshi Kosugi(Ogaki Municipal Hospital)
• Tadao Ishida(Japanese Red Cross Medical Center)

Progress in myeloma therapy: current status and future perspective

Speaker:

• Nikhil C. Munshi (Dana-Farber Cancer Institute, Harvard Medical School)

Progress in Myeloma Therapy: Current Status and Future Perspectives

Speaker:

• Daryl Tan(Mount Elizabeth Novena Hospital, Singapore)

Progress in myeloma therapy: current status and future perspective in Japan

Speaker:

• Shinsuke Iida(Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences)

Symposium 4General management of myeloma patients

May 28 (Sun.) 11:15～12:05 Room 1 (5F Main Hall)

Chairpersons:

• Yasuhito Terui(Saitama Medical University Hospital)
• Masaki Ri(Nagoya City University Hospital)

Management of Multiple Myeloma Patients: From a Viewpoint of Onco-Cardiology

Speaker:

• Hiroshi Akazawa(Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo)

Management of myeloma kidney and monoclonal gammopathy of renal significance

Speaker:

• Shinichi Mizuno(Department of Nephrology, JCHO Sendai Hospital, Sendai, Japan)

Plenary Session

May 28 (Sun.) 15:10～16:15 Room 1 (5F Main Hall)

Chairpersons:

• Masahiro Abe(Kawashima Hospital)
• Chiaki Nakaseko(International University of Health and Welfare)

The functional roles of miR-106a-5p and miR-146a-5p transferred by tumor-derived exosome in the induction of M-MDSCs in multiple myeloma

Speaker:

• Kentaro Mizuhara(Division of Hematology and Oncology, Kyoto Prefectural University of Medicine, Japan)

The anti-myeloma efficacy of TAS0612, a triple inhibitor for RSK, AKT, and S6K

Speaker:

• Haruya Okamoto(Division of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan)

Intrinsic and extrinsic regulation of BCMA expression in myeloma cells

Speaker:

• Yusuke Inoue(Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences)

Discovery of a first-in class inhibitor for histone lysine methyltransferase MMSET, which confers cytotoxicity to t(4;14)-positive multiple myeloma

Speaker:

• Sae Matsuoka(Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Japan)

The role of soluble SLAMF7-mediated inflammation in myeloma progression

Speaker:

• Takeshi Harada(Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences)

Educational Lecture 1Management for multiple myeloma based on updated guidelines

May 27 (Sat.) 11:20～11:50 Room 1 (5F Main Hall)

Chairperson:

• Shuji Ozaki(Tokushima Prefectural Central Hospital)

Speaker:

• Shigeki Ito(Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Japan)

Educational Lecture 2Pharmacokinetic aspects of drugs used for the treatment of myeloma

May 28 (Sun.) 13:15～13:45 Room 1 (5F Main Hall)

Chairpersons:

• Yutaka Hattori(Keio University / Tokyo Saiseikai Central Hospital)
• Hironobu Hashimoto(National Cancer Center Hospital)

Speaker:

• Hisakazu Ohtani(Department of Clinical Pharmacy, Keio University School of Medicine)

Oral Session 

(1) NDMM Treatment-Transplant eligible/ineligible
(2) Pathophysiology & Treatment (non-clinical) 1
(3) RRMM Treatment
(4) Diagnostic Procedure (including bio-marker)
(5) Pathophysiology & Treatment (non-clinical) 2/Case Report
(6) Myeloma-related Disorders/Others

Encore（Oral Session）1,2 

Poster Session 

(1) Pathophysiology & Treatment (non-clinical)
(2) Diagnostic Procedure (including bio-marker)/Complications, Supportive Care and Comprehensive Care
(3) NDMM Treatment-Transplant eligible/RRMM Treatment
(4) Myeloma-related Disorders/Case Report 1
(5) Case Report 2/Others

Encore（Poster Session） 

Sponsored Seminar 1How should we deal for the cancer patients complicated with COVID-19

May 26 (Fri.) 17:00～17:50 Room 1 (5F Main Hall)

Chairperson:

• Kazuhito Suzuki(The Jikei University)

Speaker:

• Osamu Kobayashi(Department of Infectious Disease, National Cancer Center Hospital)

Sponsored by GlaxoSmithKline K.K.

Sponsored Seminar 2Positioning of CD38 monoclonal antibody (Daratumumab) for the treatment
of Multiple Myeloma and Systemic AL Amyloidosis

May 26 (Fri.) 18:00～18:50 Room 1 (5F Main Hall)

Chairperson:

• Tadao Ishida(Japanese Red Cross Medical Center)

Multifaced benefits with daratumumab-containing treatment for untreated transplant-ineligible multiple myeloma

Speaker:

• Junya Kuroda(Division of Hematology and Oncology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Japan)

Treatment strategy of AL amyloidosis

Speaker:

• Shin-ichi Fuchida(Department of Hematology, JCHO Kyoto Kuramaguchi Medical Center)

Sponsored by Janssen Pharmaceutical K.K.

Sponsored Seminar 3About the well-being of patients with multiple myeloma

May 27 (Sat.) 10:25～11:15 Room 1 (5F Main Hall)

Chairperson:

• Yotaro Tamai(Shonan Kamakura General Hospital)

Experience with Safe Use of Carfilzomib through Risk Assessment, Early Detection, and Intervention of Cardiac-Related Adverse Events

Speaker:

• Yusuke Koba(Department of Hematology, Hyogo Prefectural Amagasaki General Medical Center)

Making the best use of carfilzomib for the well-being of multiple myeloma patients

Speaker:

• Morio Matsumoto(National Hospital Organization, Shibukawa Medical Center)

Sponsored by ONO PHARMACEUTICAL CO., LTD.

Sponsored Seminar 4Chromosomal abnormalities in multiple myeloma:
which ones to assess? With which technique?

May 27 (Sat.) 10:25～11:15 Room 2 (5F Large Hall)

Chairperson:

• Naoki Hosen(Osaka University)

Speaker:

• Hervé Avet-Loiseau(IUC-ONCOPOLE, France)

Sponsored by AbbVie GK

Sponsored Seminar 5Current status and issues of CAR-T cell therapy for multiple myeloma in a
routine practice

May 27 (Sat.) 16:30～17:20 Room 1 (5F Main Hall)

Chairperson:

• Junya Kuroda(Kyoto Prefectural University of Medicine)

Speaker:

• Masaki Ri(Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Japan / Division of Blood Transfusion and Cell Therapy, Nagoya City University Hospital, Japan)

Sponsored by Bristol-Myers Squibb K.K.

Sponsored Seminar 6CAR T-cell therapy for multiple myeloma

May 28 (Sun.) 10:15～11:05 Room 1 (5F Main Hall)

Chairperson:

• Masahiro Abe(Kawashima Hospital / Tokushima University)

Speaker:

• Satoshi Yoshihara(Department of Respiratory Medicine and Hematology, Hyogo Medical University, Japan)

Sponsored by Janssen Pharmaceutical K.K.

Sponsored Seminar 7Clinical Trial Evidence to Real-World Evidence

May 28 (Sun.) 10:15～11:05 Room 2 (5F Large Hall)

Chairperson:

• Hirohiko Shibayama(National Hospital Organization, Osaka National Hospital)

Speaker:

• Teruhito Takakuwa(Department of Hematology, Graduate School of Medicine, Osaka Metropolitan University)

Sponsored by Takeda Pharmaceutical Company Limited

Morning Seminar 1Treatment strategies for Lymphoplasmacytic Lymphoma/ Waldenström's Macroglobulinemia -including our experiences treating Bing–Neel syndrome-

May 28 (Sun.) 8:00～8:40 Room 1 (5F Main Hall)

Chairperson:

• Naohiro Sekiguchi(National Hospital Organization, Disaster Medical Center)

Speaker:

• Masuho Saburi(Department of Hematology, Oita Prefectural Hospital, Japan)

Sponsored by ONO PHARMACEUTICAL CO., LTD.

Morning Seminar 2Response evaluation on patients undergoing anti-CD38 therapy, Daratumumab and Isatuximab, should be determined by the HYDRASHIFT assays

May 28 (Sun.) 8:00～8:40 Room 2 (5F Large Hall)

Chairperson:

• Hiroyuki Takamatsu(Kanazawa University)

Speaker:

• Kazunori Miyake(Department of Clinical Laboratory, Cancer Institute Hospital of Japanese Foundation for Cancer Research / Faculty of Medical Science, Juntendo University)

Sponsored by SEBIA JAPAN K.K.

Luncheon Seminar 1The significance of the combination therapy of daratumumab and IMiDs for
multiple myeloma from scientific and clinical aspects

May 27 (Sat.) 12:00～12:50 Room 1 (5F Main Hall)

Chairperson:

• Chiaki Nakaseko(International University of Health and Welfare)

Reshaping a treatment paradigm in multiple myeloma with the development of immunotherapeutic modalities

Speaker:

• Takeshi Harada(Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences）

Real-world experience of DRd regimen for transplant-ineligible newly diagnosed multiple myeloma

Speaker:

• Yuichi Horigome(Department of Hematology, Kitasato University Graduate School of Medical Sciences, Japan)

Sponsored by Janssen Pharmaceutical K.K.

Luncheon Seminar 2The positioning of PI continuation therapy in MM treatment sequence

May 27 (Sat.) 12:00～12:50 Room 2 (5F Large Hall)

Chairperson:

• Hirokazu Murakami(Gunma University of Health and Welfare)

Treatment strategy of MM considering the treatment sequence
-The significance of maintenance therapy -

Speaker:

• Kenshi Suzuki(Department of Hematology, Japanese Red Cross Medical Center)

Multiple myeloma treatment strategy considering the treatment sequence
-Updates on PI continuous therapy in RRMM-

Speaker:

• Naoki Takezako(Nerima-Hikarigaoka Hospital Department of Hematology)

Sponsored by Takeda Pharmaceutical Company Limited

Luncheon Seminar 3Two years have passed since the Sarclisa® have launched-Considering
the position of Sarclisa from the basic and clinical perspectives

May 28 (Sun.) 12:15～13:05 Room 1 (5F Main Hall)

Chairperson:

• Shuji Ozaki(Tokushima Prefectural Central Hospital)

Speakers:

• Yusuke Furukawa(Center for Medical Education, Teikyo University of Science / Center for Molecular Medicine, Jichi Medical University)
• Takashi Ikeda(Shizuoka Cancer Center)

Sponsored by Sanofi K.K.

Luncheon Seminar 4Treatment Sequence considering Tumor and the Immune Microenvironment

May 28 (Sun.) 12:15～13:05 Room 2 (5F Large Hall)

Chairperson:

• Kazutaka Sunami(NHO Okayama Medical Center)

The clinical application of myeloma microenvironment evaluation

Speaker:

• Michiko Ichii(Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Japan)

Multiple myeloma treatment sequence in the immune-based therapy era, including timing of pomalidomide-intensified antibody treatment

Speaker:

• Hideto Tamura(Division of Diabetes, Endocrinology and Hematology, Department of Internal Medicine, Dokkyo Medical University Saitama Medical Center, Japan)

Sponsored by Bristol-Myers Squibb K.K.